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Jeffrey S Robinson1, for the A*STEROID Study GroupAbstract
Background: Both dexamethasone and betamethasone, given to women at risk of preterm birth, substantially
improve short-term neonatal health, increase the chance of the baby being discharged home alive, and reduce
childhood neurosensory disability, remaining safe into adulthood. However, it is unclear which corticosteroid is of
greater benefit to mother and child.
This study aims to determine whether giving dexamethasone to women at risk of preterm birth at less than 34
weeks’ gestation increases the chance of their children surviving free of neurosensory disability at two years’
corrected age, compared with betamethasone.
Methods/Design: Design randomised, multicentre, placebo controlled trial.
Inclusion criteria women at risk of preterm birth at less than 34 weeks’ gestation with a singleton or twin pregnancy and
no contraindications to the use of antenatal corticosteroids and who give informed consent.
Trial entry & randomisation at telephone randomisation eligible women will be randomly allocated to either the
dexamethasone group or the betamethasone group, allocated a study number and corresponding treatment pack.
Study groups women in the dexamethasone group will be administered two syringes of 12 mg dexamethasone
(dexamethasone sodium phosphate) and women in the betamethasone group will be administered two syringes of 11.4
mg betamethasone (Celestone Chronodose). Both study groups consist of intramuscular treatments 24 hours apart.
Primary study outcome death or any neurosensory disability measured in children at two years’ corrected age.
Sample size a sample size of 1449 children is required to detect either a decrease in death or any neurosensory disability
from 27.0% to 20.1% with dexamethasone compared with betamethasone, or an increase from 27.0% to 34.5%
(two-sided alpha 0.05, 80% power, 5% loss to follow up, design effect 1.2).
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Discussion: This study will provide high-level evidence of direct relevance for clinical practice. If one drug clearly results
in significantly fewer deaths and fewer disabled children then it should be used consistently in women at risk of preterm
birth and would be of great importance to women at risk of preterm birth, their children, health services and
communities.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12608000631303
Keywords: Antenatal corticosteroids, Dexamethasone, Betamethasone, Preterm birth, Randomised controlled trial,
Neurosensory disabilityBackground
Children born preterm have a higher than average risk of
dying in the first weeks of life and survivors experience
higher rates of neurosensory disability than children born
at term [1,2]. There is clear evidence that antenatal corti-
costeroids, both dexamethasone and betamethasone, given
to women at risk of preterm birth substantially improve
short-term neonatal health, increase the chance of the
baby being discharged home alive, and reduce childhood
neurosensory disability, remaining safe into adulthood [3].
The type of antenatal corticosteroid to use in clinical
practice remains unclear [3]. Dexamethasone and betame-
thasone are both recommended [4] and widely used [1].
Is dexamethasone better than betamethasone, or vice
versa? Our meta-analysis, using the limited data available
from randomised trials that have directly compared the
two treatments shows that dexamethasone reduces the
risk of the baby developing intraventricular haemorrhage
(IVH) to a greater extent than betamethasone [5]. While
reduced IVH is a very important outcome, achieving a
reduction in long-term survival free of any disability is
the most important goal [2]. Data regarding the effects
on long-term health are sparse.Preterm birth and antenatal corticosteroids
One of the major advances in maternal fetal medicine
over the last 35 years has been the evaluation and imple-
mentation into clinical practice of administration of
antenatal corticosteroids to women at risk of preterm
birth [3]. Corticosteroids remain the ‘gold standard’
antenatal intervention to reduce the risk of fetal and
neonatal mortality related to preterm birth.
Meta-analysis of the 21 randomised trials (14 using
betamethasone, six using dexamethasone, one unknown,
using a wide range of different treatment regimens, in
3885 women and 4269 infants) included in the Cochrane
Systematic Review “Antenatal corticosteroids for accele-
rating fetal lung maturation” [3] shows that, compared
with placebo, both dexamethasone and betamethasone
have large and clinically substantial beneficial effects
compared with controls on the risk of fetal and neonatal
death, respiratory distress syndrome, intraventricularhaemorrhage (IVH) and long-term neurological sequelae
[3]. Thirty years after antenatal betamethasone treat-
ment, health outcomes are generally good, apart from
indirect evidence of possible mild insulin resistance [6],
but there have been no follow-up studies of similar dura-
tion for dexamethasone.
Clinical practice guidelines for the use of antenatal
corticosteroids have been developed by many colleges
and institutions [7,8], often based on the NIH Consensus
Panel Guidelines that were first released in 1994 [9], and
again in 2000 [4]. These guidelines state that “All preg-
nant women between 24 and 34 weeks gestation who
are at risk of preterm delivery within 7 days should be
considered candidates for antenatal treatment with a
single course of corticosteroids” [4].Corticosteroid type and regimen in current clinical
practice
There is considerable variation between countries as to
whether dexamethasone or betamethasone is used in clin-
ical practice. There are likely to be many reasons for these
differences including availability, costs [10] (dexame-
thasone is cheaper than betamethasone so is widely used
in low-income countries), impact of non-randomised,
observational studies on efficacy and safety [11,12] and
influence of opinion leaders [13]. In Australia and New
Zealand both preparations are used, betamethasone most
frequently [14].
The optimal treatment regimen to use for antenatal
corticosteroids is uncertain. The current Cochrane review
“Antenatal corticosteroids for accelerating fetal lung
maturation” presents no evidence on an optimal dosing
regimen [3]. An earlier version of this Cochrane review
[15] mentioned “a policy of administering corticosteroids
(24 mg betamethasone, or 24 mg dexamethasone)”, with-
out specifying treatment regimens in detail. The NIH
Consensus Statement, based on information available in
the late 1990s, recommended “two doses of 12 mg of
betamethasone given intramuscularly 24 hours apart or
four doses of 6 mg of dexamethasone given intramuscularly
12 hours apart” [4]. Since 2000 there have been four further
trials, some using different treatment regimens, and these
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review authors highlighting that “further research is
required to determine the optimal dose to use” [3].
Given this uncertainty it is not surprising to find a
variety of different treatment regimens used in clinical
care. For instance, to complete a course of antenatal
corticosteroids, 48% of practitioners in Australia and New
Zealand prescribe two injections at 12 hour intervals and
43% prescribe two injections at 24 hour intervals, with
variation for both dexamethasone and betamethasone
[14]. Practice is similarly varied in the UK [16]. To com-
plete a course of 24 mg dexamethasone over 24 hours, the
treatment regimen varies between institutions, and even
within institutions, and includes 8 mg for 3 doses 8 hours
apart [17], 12 mg for two doses 12 hours apart [17,18], or
12 mg for two doses 24 hours apart [18,19].
Evidence from non-randomised cohort studies using
dexamethasone or betamethasone
There have been several recent non-randomised, retro-
spective human studies comparing antenatal dexametha-
sone and betamethasone [11,12,20-22], and particularly
their effects on IVH and periventricular leukomalacia;
both major precursors for cerebral palsy. Results are
conflicting, with some studies reporting no differences in
the risk of IVH [12,21,22], periventricular leukomalacia
[11,21,22], or mortality [12,21,22], but others report that
dexamethasone is associated with an increase in periven-
tricular leukomalacia [12] and neurosensory impairment
[20]. The inherent risk of bias with retrospective study
designs should limit the conclusions drawn for clinical
practice, but this caution is not always mentioned
[11,13,20-22]. Furthermore, it is possible that some effects
of dexamethasone on periventricular leukomalacia may be
attributable to the sulphite preservative used in some
formulations rather than the drug itself, as shown in a
mouse model [23].
Appraising the evidence - the cochrane review
Evidence from randomised controlled trials using
dexamethasone or betamethasone: effect on childhood
health - reduction in neurosensory disability
Five randomised trials (908 children) with long-term
follow-up are included in the Roberts Cochrane system-
atic review; [3] three comparing antenatal betamethasone
with placebo [24-26], and two comparing dexamethasone
with placebo [27,28].
Compared with placebo, both antenatal dexamethasone
and betamethasone were associated with less developmen-
tal delay in childhood (Relative Risk (RR) 0.49, 95% Confi-
dence Interval (CI) 0.24 to 1.00, 2 trials, 518 children), and
a trend towards fewer children having cerebral palsy
(RR 0.60, 95% CI 0.34 to 1.03, 5 trials, 904 children) [3].
Authors in the Roberts’ review emphasise that their reviewdoes not suggest evidence of a difference in risk of cere-
bral palsy between betamethasone and dexamethasone.
Highlighting this research gap they state “Future studies
are needed to determine the optimal drug” [3].
Evidence from randomised trials: direct comparison of
dexamethasone with betamethasone
We have conducted a Cochrane systematic review to
assess the use of different corticosteroids and regimens
for accelerating fetal lung maturation for women at risk
of preterm birth [5].
Five trials met the inclusion criteria [29-33]. No health
outcomes of relevance for the mother were reported
from any of the trials. For the infant, antenatal exposure
to dexamethasone was associated with a significantly
lower risk of IVH than exposure to betamethasone (3.5%
versus 6.9%, RR 0.44 95% CI 0.21 to 0.92, 4 trials, 717
infants). No significant difference was seen for respiratory
distress syndrome, severe intraventricular haemorrhage,
periventricular leukomalacia or death. Information on
childhood outcomes is limited to a single trial that repor-
ted one instance of neurosensory disability among only 12
infants admitted to neonatal intensive care unit and
followed up at 18 months [33].
We conclude from this systematic review that high
quality randomised controlled trials comparing dexa-
methasone and betamethasone are needed. Trials must
be adequately powered to be able to detect important
differences, not only in neonatal outcomes but also in
survival and health into childhood.
Aims and objectives of this trial
The primary aim of this randomised controlled trial is to
determine whether giving antenatal dexamethasone to
women at risk of preterm birth at less than 34 weeks’
gestation increases the chance of their children surviving
free of neurosensory disability at two years’ corrected age,
compared with women given antenatal betamethasone.
Hypotheses
The primary hypothesis of the study is that, compared
with betamethasone, antenatal dexamethasone given to
women at risk of preterm birth (less than 34 weeks’
gestation) reduces the risk of death or any neurosensory
disability, caused by impairments such as cerebral palsy,
blindness, deafness or developmental delay, in their
children at two years’ corrected age.
The secondary hypotheses are that compared with
betamethasone, antenatal dexamethasone treatment has
benefits up to the time of primary hospital discharge,
relating to: the baby, of neonatal morbidity; and the
mother, of maternal infections, and quality of life; and at
two years’ corrected age, relating to individual compo-
nents of the primary outcome and body size, respiratory
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Ethics approval was granted by the Children’s Youth and
Women’s Health Services Human Research Ethics Com-
mittee at the Women’s and Children’s Hospital (REC2074/
7/14) and by the local institutional review boards for each
centre.
Study design
Randomised, multicentre, placebo controlled trial.
Inclusion criteria
Women are eligible for the trial if they are at risk of pre-
term birth at less than 34 weeks gestation, have a single-
ton or twin pregnancy, no contraindications to the use
of antenatal corticosteroids and give informed consent.
Exclusion criteria
Women are not eligible if they have chorioamnionitis
requiring urgent delivery, a higher order multiple preg-
nancy, have already received antenatal corticosteroids,
have known fetal lung maturation, or are in the second
stage of labour.
Trial entry
All eligible women will be given the trial information
sheet, counselled by a member of the research team and
encouraged to discuss the study with her family before
written informed signed consent is sought.
Study groups
Once all entry details are given and eligibility is confirmed,
the woman is randomised by contacting the central
telephone randomisation service at the University of
Adelaide. Assignment to one of two study groups: either
the dexamethasone group or the betamethasone group
will be stratified for collaborating centre, gestational age
(<28 weeks’, ≥28 weeks’ gestation), and number of fetuses
(1 or 2). A Study Number will be allocated to the woman
corresponding to a treatment pack, each of which looks
identical and contains two opaque study-labelled syringes.
Dexamethasone study group Women randomised to
the dexamethasone study group will receive the contents
of the two syringes intramuscularly 24 hours apart, each
containing 12 mg dexamethasone (as dexamethasone so-
dium phosphate - a non-sulphite containing preparation).
Betamethasone study group Women randomised to
the betamethasone study group will receive the contents
of the two syringes intramuscularly 24 hours apart, eachcontaining 11.4 mg betamethasone (as Celestone
Chronodose 11.4 mg).
Both study groups At weekly intervals, if the woman has
not yet given birth, and remains at continued risk of
preterm birth, justifying the use of repeat antenatal corti-
costeroids [34-36], a ‘repeat treatment pack’ containing a
single syringe from the same treatment group will be
allocated using the telephone randomisation service.
Care during the antenatal period, labour and postnatal
stay will be managed by the obstetric team caring for the
woman. Care of the neonate will be the responsibility of
the attending neonatologist.
Follow up after birth until the time of primary discharge
for both groups
The pregnancy and labour data will be abstracted from
case notes by the masked research assistant at the
collaborating hospitals. The postnatal and neonatal data
will be collected similarly after discharge of the mother
and baby from hospital.
Longer term follow up
Parents enrolled in the trial will give consent for follow-
up of their children from birth until two years’ corrected
age at the time of the initial, prenatal recruitment.
Mothers of all babies discharged home alive will be
contacted by a member of the study team from the co-
ordinating centre by mail soon after their baby is
discharged and then again when their baby is six, 12 and
18 months corrected age. Mothers will be provided with
a reply paid envelope and asked to confirm their current
contact details by mail. At each of these times, a mem-
ber of the study team at the coordinating centre will
contact the parents by telephone if a response has not
been received in the mail.
Two years assessments
All surviving children will be formally assessed at two
years of age, corrected for prematurity, by a developmen-
tal paediatrician and psychologist or other trained assessor
who can administer the Bayley Scales, all of whom remain
blinded to treatment group assignment. The parents will
be contacted by the follow-up coordinator at the recruit-
ment hospital to organise this appointment. However, if
the family does not live close to this hospital, a member of
the study team at the coordinating centre will telephone
them to discuss a suitable alternative. Assessments will be
made of health, neurodevelopment, behaviour, growth and
blood pressure.
Motor function
The paediatric assessment will include a neurological
examination to diagnose cerebral palsy (loss of motor
Table 1 Neurosensory disability classifications [37]
Severe disability Any severe cerebral palsy (child non-ambulant
and likely to remain so; GMFCS level 4 or 5),
severe developmental delay (standardised
score <−3 SD) or blindness.
Moderate disability Moderate cerebral palsy (child non-ambulant at
2 years of age but who is likely to ambulate
subsequently; GMFCS level 2 or 3), or deafness,
or moderate developmental delay (standardised
score from −3 SD to <−2 SD).
Mild disability Mild cerebral palsy (child walking at 2 years of
age with only minimal limitation of movement
(GMFCS level 1), or suspect developmental delay
(standardised score from −2 SD to <−1 SD).
No neurosensory
disability
Children without any neurosensory impairment.
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and other disability outcomes according to previously
reported criteria [37]. The severity of gross motor func-
tion in children will be classified using the Gross Motor
Function Classification System (GMFCS) [38].
Psychological assessments
The psychological assessment will include the cognitive,
motor and language scales of the Third Edition of the
Bayley Scales of Infant Development (BSID-III) [39]. This is
well-standardised with demonstrated validity and reliability.
Psychological test scores will be recorded as a standardised
normal score [derived from test score - mean/standard
deviation (SD)]. Children with severe developmental delay
who are unable to complete the psychological assessment
will be given a standardised score of - 4 SD.
Behaviour
The child’s caregiver will be asked to complete the Child
Behaviour Checklist [40].
General health, health resource utilisation, blood
pressure, body size, and quality of life A general
history and physical examination will determine the pre-
sence of any significant chronic illness, and data regarding
hospital readmissions will be confirmed, where necessary,
from the admitting hospital or doctor. Children will be
considered blind if visual acuity in both eyes is worse than
6/60. Children will be considered deaf if their hearing loss
is sufficient to require hearing aid(s), or worse. Blood pres-
sure will be measured and converted to Z-scores relative
to American data for blood pressure for age, height and
gender in childhood [41].
Questionnaires will be completed by the child’s
caregiver about any respiratory morbidity, history of
illness or injury and use of health services since primary
hospitalisation.
The child’s height, weight, and head circumference will
be measured in the standard way, and values for the
relevant centile, percent of median, and standard deviation
scores (Z scores) specific for age and gender will be com-
puted from the British Growth Reference [42].
Categorisation of neurosensory disability
Children will be considered to have a neurosensory
impairment if they have cerebral palsy, blindness, deaf-
ness or any of the Bayley Scale scores more than 1 SD
below the mean (<−1 SD). The neurosensory disabilities
imposed by the various neurosensory impairments will
be classified as severe, moderate or mild [37] (Table 1).
Primary study endpoints
The primary study endpoint measured in the children at
two years’ corrected age is the incidence of death or anyneurosensory disability defined as stillbirths, deaths from
live born infants before hospital discharge and deaths
after hospital discharge; and any neurosensory disabi-
lities that include the neurosensory impairments of cere-
bral palsy, blindness, deafness and any developmental
delay defined as a standardised score more than 1 SD
below the mean (<−1 SD).
Secondary study endpoints
For the infant/child
 Death or major neurosensory disability (with major
neurosensory disability defined as severe and
moderate disability and includes blindness, deafness,
cerebral palsy in a child non-ambulant by two years
of age or a standardised score <−2 SD).
 Individual components and severity of the primary
outcome (death, cerebral palsy, blindness, deafness,
developmental delay).
 Neonatal outcomes measured prior to primary
hospital discharge, including IVH, severe IVH
(Grade 3 or 4), periventricular leukomalacia,
retinopathy of prematurity needing treatment,
patent ductus arteriosus needing treatment,
respiratory distress syndrome, severity of any
neonatal lung disease, chronic lung disease (need for
oxygen at 36 weeks post-menstrual age or 28 days of
life if born after 32 weeks gestation), use of
mechanical ventilation, confirmed infection within
the first 48 hours, infection after the first 48 hours,
proven necrotising enterocolitis, body size at birth
(weight, length and head circumference) and at
discharge home after birth.
 Childhood outcomes assessed at two years’
corrected age including body size and corresponding
Z scores, general health of the child (including use
of health services since primary hospitalisation),
childhood respiratory morbidity, blood pressure Z
scores and proportions in hypertensive ranges and
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Checklist [40].
For the mother
 Maternal perinatal infectious morbidity (defined as
clinical chorioamnionitis requiring intrapartum
antibiotics and/or use of postpartum antibiotics).
Sample size
With a predicted mortality rate of 6.05% up to two years
and a predicted rate of neurosensory disability in survivors
of 20.9%, we estimate the rate of our primary outcome of
death or neurosensory disability at two years corrected
age in an Australian/New Zealand population exposed
antenatally to betamethasone to be 27.0% [3,37,43,44].
A trial of 1499 children, allowing 5% loss to follow up
and with a design effect of 1.2 to allow for the clustering
of babies within mothers, will have 80% power to detect
a statistically significant difference at an alpha level of
0.05 (two-tailed) of either:
 a decrease in the combined outcome of death or
neurosensory disability from 27.0% to 20.1%
(Absolute Risk Difference (ARD) 6.9%; Relative Risk
Difference (RRD) 25.6%) with dexamethasone
compared with betamethasone, or;
 an increase from 27.0% to 34.5% (ARD 7.5%;
RRD 27.8%).
Analysis and reporting of results
Data will be analysed by a statistician independent of the
clinical investigators. Potential confounding variables will
comprise sociodemographic variables, such as ethnicity,
language spoken at home, family structure, mother’s mari-
tal status, social class, and mother’s and father’s education,
as well as gender. Comparisons will be made between
treatment groups for the primary and secondary end-
points using an intention to treat approach. Analyses will
make adjustments for the stratification variables and for
important baseline predictors including gestational age at
trial entry, and reasons for risk of preterm birth. Un-
adjusted analyses will also be performed. Log binomial re-
gression and linear regression will be used to examine
dichotomous and continuous outcomes respectively, with
results presented as relative risks or differences in means
along with 95% confidence intervals. Adjustment will
be made for clustering due to multiple births for in-
fant outcomes using generalised estimating equations.
P-values < 0.05 will be considered statistically significant.
Discussion
Administration of antenatal corticosteroids, both dexa-
methasone and betamethasone, given to women at riskof preterm birth, leads to substantial benefits for babies
born preterm. Although this cost-effective treatment is
widely used in practice throughout the world, there is
uncertainty as to which drug treatment is of greatest
benefit. Clearly, large, high quality randomised con-
trolled trials are a priority to provide high-level evidence
for clinical practice. If one drug clearly results in signifi-
cantly fewer deaths and fewer disabled children then it
should be used consistently in women at risk of preterm
birth and would be of great importance to women at risk
of preterm birth, their children, health services and
communities.
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